The FAAH inhibitor JNJ-42165279 (101) is currently being evaluated for the treatment of PTSD in a 12-week randomized controlled trial of 90 individuals with PTSD that combines evaluation of established clinical end points with neuroimaging and psychophysiology-based experimental biomarkers, including fear extinction and functional magnetic resonance imaging measures of vmPFC–amygdala connectivity (EudraCT 2020–001965-36). The gene discussed is FAAH; the disease is post-traumatic stress disorder.